Vasculitis
Drug research and approvals for vasculitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 185 studies of vasculitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 3 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 185
- Trials authorized in Canada: 3
- FDA orphan approvals: 3
- EU medicines: 0
Recruiting Now
Newest start dates first, of 185 recruiting on ClinicalTrials.gov ↗- Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeNCT07556484 · Phase 1 · Mayo Clinic · starts Aug 1, 2027
- Gryrotonic Training in Behcet-diseased Elders With Breast CancerNCT07929116 · Not applicable · Cairo University · starts Nov 30, 2026
- Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · Not reported · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · starts Nov 9, 2026
- FT839 in Autoimmune DiseasesNCT07800871 · Phase 1 / Phase 2 · Fate Therapeutics · starts Oct 1, 2026
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic…NCT07822100 · Not applicable · Hong Zhang · starts Aug 24, 2026
- Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated GlomerulonephritisNCT07746180 · Phase 2 · Chinese PLA General Hospital · starts Aug 21, 2026
- Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of…NCT07595367 · Phase 2 · Qifeng Zhang · starts Aug 10, 2026
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit…NCT07444567 · Phase 3 · AstraZeneca · starts Jul 24, 2026
- Statins Study in Children of Acute Kawasaki Disease With Coronary Artery AbnormalitiesNCT07530640 · Phase 3 · Children's Hospital of Fudan University · starts Jun 8, 2026
Drug Pipeline
7 in phase 3, 2 in phase 2, 5 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Avacopan
- Phase 3 C5a anaphylatoxin chemotactic receptor antagonist
- Azathioprine
- Phase 3 Amidophosphoribosyltransferase inhibitor
- Ibuprofen
- Phase 3 Cyclooxygenase inhibitor
- Methotrexate
- Phase 3 Dihydrofolate reductase inhibitor
- Prednisone
- Phase 3 Glucocorticoid receptor agonist
- Colchicine
- Phase 3 Tubulin inhibitor
- Belimumab
- Phase 3 Tumor necrosis factor ligand superfamily member 13B inhibitor
- Mycophenolate mofetil
- Phase 2 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Cyclophosphamide anhydrous
- Phase 2 DNA inhibitor
- Alemtuzumab
- Phase 1 CAMPATH-1 antigen inhibitor
- Fludarabine
- Phase 1
- Tacrolimus anhydrous
- Phase 1 FK506-binding protein 1A inhibitor
- 2-MERCAPTOETHANESULFONIC acid
- Phase 1 Unknown
- Filgrastim
- Phase 1 Granulocyte colony stimulating factor receptor agonist
How Its Trials Ended
253 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 40 whose ending is known, 38% met their primary endpoint, 5% missed it and 57% stopped early.
- Ongoing9638%
- Completed, result not reported7329%
- Status unknown4417%
- Met its primary endpoint156%
- Stopped: other or unclear135%
- Stopped: enrollment or feasibility62%
- Stopped: funding31%
- Missed its primary endpoint21%
- Stopped: sponsor or business decision10%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Nov 25, 2025 | A randomized, double blind, placebo controlled phase 4 clinical trial to evaluate the long-term safety and efficacy of avacopan in participants with…Avacopan (amg 569) | Amgen | Pending |
| Aug 28, 2025 | Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of tarperprumig in adult…Tarperpruming (ALXN1820) | AstraZeneca Pharmaceuticals | Ongoing |
| Oct 15, 2024 | A phase 3, open-label, uncontrolled single-arm study to evaluate the efficacy, pharmacokinetics, and safety of avacopan in combination with a rituximab or a…Avacopan (amg 569) | Amgen | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Oct 7, 2021 | TavneosAs an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis… | ChemoCentryx, Inc. | Approved |
| Sep 27, 2019 | RituxanRITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with… | Genentech, Inc. | Approved |
| Apr 19, 2011 | RituxanFor the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and… | Genentech, Inc. | Approved |
| Feb 19, 2026 | A humanized IgG4 mAb that binds to hC5aR1 and blocks C5a…Treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis | Otsuka Pharmaceutical Development & Commercialization, Inc | Designated |
| Sep 18, 2020 | GabexateTreatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis | RNR BioMedical Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA